Brooks Laboratories Ltd
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]
- Market Cap ₹ 289 Cr.
- Current Price ₹ 98.0
- High / Low ₹ 203 / 93.5
- Stock P/E 20.7
- Book Value ₹ 39.3
- Dividend Yield 0.00 %
- ROCE -9.93 %
- ROE -12.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Company has a low return on equity of -21.8% over last 3 years.
- Earnings include an other income of Rs.13.9 Cr.
- Promoter holding has decreased over last 3 years: -13.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 77 | 91 | 63 | 79 | 83 | 93 | |
| 77 | 105 | 93 | 97 | 91 | 90 | |
| Operating Profit | 1 | -14 | -30 | -18 | -8 | 3 |
| OPM % | 1% | -16% | -47% | -22% | -10% | 3% |
| 1 | 1 | 1 | 1 | 1 | 14 | |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 |
| Profit before tax | -9 | -24 | -38 | -20 | -10 | 14 |
| Tax % | 115% | -19% | -19% | 0% | 2% | |
| -19 | -19 | -31 | -20 | -10 | 14 | |
| EPS in Rs | -7.40 | -4.31 | -7.97 | -7.46 | -3.38 | 4.65 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -3% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| TTM: | 170% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 8% |
| 3 Years: | -6% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -22% |
| Last Year: | -12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 86 |
| 31 | 25 | 7 | 6 | 8 | 8 | |
| 52 | 83 | 29 | 19 | 18 | 16 | |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 140 |
| 108 | 110 | 15 | 14 | 14 | 13 | |
| CWIP | 1 | 15 | -0 | -0 | -0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 86 |
| 54 | 71 | 31 | 34 | 36 | 40 | |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 140 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 4 | -37 | -14 | -10 | 3 | |
| -5 | -25 | 0 | 0 | -45 | |
| 1 | 64 | 11 | 10 | 42 | |
| Net Cash Flow | 0 | 2 | -3 | 0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 65 | 71 | 74 | 75 | 88 |
| Inventory Days | 178 | 157 | 80 | 60 | 61 |
| Days Payable | 233 | 159 | 165 | 97 | 90 |
| Cash Conversion Cycle | 9 | 68 | -12 | 38 | 59 |
| Working Capital Days | -85 | 34 | -37 | 34 | 43 |
| ROCE % | -16% | -30% | -25% | -10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Publication dated 15th November 2025 of the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2025.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, 14Th November 2025.
14 Nov - Board approved unaudited quarter and half-year results to 30 Sep 2025; consolidated H1 profit Rs1,756.17 lakhs.
-
Results For Quarter And Half Year Ended 30Th September 2025
14 Nov - Unaudited Q2/H1 results to 30 Sep 2025: standalone H1 revenue Rs4,896.26L; consolidated H1 PAT Rs1,756.17L.
-
Announcement under Regulation 30 (LODR)-Credit Rating
12 Nov - CARE upgraded long-term to CARE BB (Stable) for ₹7.80cr; short-term CARE A4 reaffirmed for ₹4.20cr.
-
Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
7 Nov - Board meeting 14 Nov 2025 to approve unaudited Q2/H1 results ended 30 Sep 2025; trading window reopens 48h after.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BLL is an EU GMP & ISO 9001:2008 certified manufacturer and marketer of pharmaceutical formulations